0001415889-24-004003.txt : 20240215
0001415889-24-004003.hdr.sgml : 20240215
20240215204002
ACCESSION NUMBER: 0001415889-24-004003
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Regnante Keith
CENTRAL INDEX KEY: 0001682068
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 24645550
MAIL ADDRESS:
STREET 1: 733 CONCORD AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811173868
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-314-6297
MAIL ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
form4-02162024_010256.xml
X0508
4
2024-02-13
0001664710
Keros Therapeutics, Inc.
KROS
0001682068
Regnante Keith
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
LEXINGTON
MA
02421
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Employee Stock Option (right to buy)
56.18
2024-02-13
4
A
0
40000
0
A
2034-02-12
Common Stock
40000
40000
D
25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante
2024-02-15